Defence Therapeutics (DTC) Ratios
Defence Therapeutics Ratios
DE:DTC's free cash flow for Q4 2026 was $-1.04M. For the 2026 fiscal year, DE:DTC's free cash flow was decreased by $-404.58K and operating cash flow was $-632.53K. See a summary of the company’s cash flow.
| Ratios | Jun 26 | Sep 25 | Jun 24 | Sep 23 | Sep 22 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.42 | 0.50 | 0.05 | 15.58 | 0.61 |
| Quick Ratio | 3.42 | 0.50 | 0.05 | 15.58 | 0.61 |
| Cash Ratio | 1.47 | 0.42 | 0.01 | 12.67 | 0.46 |
| Solvency Ratio | -2.21 | -1.19 | -3.23 | -3.43 | -0.06 |
| Operating Cash Flow Ratio | -3.39 | -1.17 | -1.06 | -34.73 | -5.46 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -2.28 | -2.51 | 0.00 | 0.00 |
| Net Current Asset Value | $ 1.38M | $ -1.44M | $ -3.85M | $ 1.47M | $ -433.58K |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.26 | 0.91 | 3.66 | 0.49 | 0.00 |
| Debt-to-Equity Ratio | 0.49 | -1.20 | -0.49 | 1.11 | 0.00 |
| Debt-to-Capital Ratio | 0.33 | 6.06 | -0.95 | 0.53 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.33 | 0.00 | 0.00 | 0.53 | 0.00 |
| Financial Leverage Ratio | 1.85 | -1.32 | -0.13 | 2.26 | -1.86 |
| Debt Service Coverage Ratio | -11.76 | -1.73 | -6.01 | -24.25 | 0.00 |
| Interest Coverage Ratio | -12.15 | -10.14 | -31.81 | -24.89 | 0.00 |
| Debt to Market Cap | 0.06 | 0.04 | 0.05 | 0.02 | 0.00 |
| Interest Debt Per Share | 0.03 | 0.04 | 0.05 | 0.05 | 0.00 |
| Net Debt to EBITDA | 0.03 | -0.09 | -0.13 | 0.16 | 0.00 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 98.72% | 100.00% | 100.00% | 98.47% | 100.00% |
| EBT Per EBIT | 135.91% | 107.75% | 104.25% | 104.93% | 206.30% |
| Return on Assets (ROA) | -102.88% | -213.26% | -2761.51% | -191.43% | -1020.47% |
| Return on Equity (ROE) | -190.75% | 280.46% | 368.09% | -431.80% | 1894.94% |
| Return on Capital Employed (ROCE) | -95.47% | 260.29% | 353.87% | -197.61% | 918.54% |
| Return on Invested Capital (ROIC) | -94.25% | -1315.83% | 688.65% | -194.59% | 918.54% |
| Return on Tangible Assets | -102.88% | -213.26% | -2761.51% | -193.56% | -1090.18% |
| Earnings Yield | -24.47% | -10.10% | -40.49% | -5.84% | -10.18% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.05 | 0.04 | 0.07 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -6720.41 | -8392.73 | -5062.66 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 6720.41 | 8392.73 | 5062.66 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.07 | -0.07 | -0.10 | -0.19 | -0.17 |
| Free Cash Flow Per Share | -0.08 | -0.07 | -0.10 | -0.19 | -0.17 |
| Dividend Paid and CapEx Coverage Ratio | -10.35 | 0.00 | -21.10 | -116.37 | -1208879.00 |
| Capital Expenditure Coverage Ratio | -10.35 | 0.00 | -21.10 | -116.37 | -1208879.00 |
| Operating Cash Flow Coverage Ratio | -2.53 | -2.26 | -2.46 | -4.39 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -17.41% | -9.75% | -13.79% | -6.67% | -8.38% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.00 | -9.90 | -2.47 | -17.12 | -9.82 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | 7.79 | -27.77 | -9.09 | 73.94 | -186.18 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -5.74 | -10.26 | -7.25 | -14.99 | -11.94 |
| Price-to-Operating Cash Flow Ratio | -6.30 | -10.26 | -7.60 | -15.12 | -11.94 |
| Price-to-Earnings Growth (PEG) Ratio | -0.07 | 0.13 | -0.03 | 1.14 | -0.12 |
| Enterprise Value Multiple | -5.53 | -11.24 | -2.70 | -17.71 | 0.00 |
| Enterprise Value | 27.20M | 35.15M | 34.27M | 114.76M | 71.65M |
| EV to EBITDA | -5.53 | -11.24 | -2.70 | -17.71 | 0.00 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -5.71 | -10.34 | -7.63 | -14.86 | -11.85 |
| EV to Operating Cash Flow | -6.26 | -10.34 | -7.99 | -14.99 | -11.85 |
| Tangible Book Value Per Share | 0.06 | -0.03 | -0.08 | 0.04 | -0.01 |
| Shareholders’ Equity Per Share | 0.06 | -0.03 | -0.08 | 0.04 | -0.01 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.01 | 0.00 | 0.00 | 0.02 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.11 | -0.07 | -0.30 | -0.17 | -0.20 |
| Tax Burden | 0.99 | 1.00 | 1.00 | 0.98 | 1.00 |
| Interest Burden | 1.36 | 1.10 | 1.04 | 1.06 | 1.01 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.65 | 0.97 | 0.33 | 1.13 | 0.82 |
Currency in CAD